Drug value assessments generally fail to account for the complexities of health care systems and thus can misinform price negotiations and lead to overly restrictive access policies. Our new article in Health Affairs Forefront explores how more thorough systems thinking can yield more realistic evaluations of the impact of new therapies.
In the article, coauthored with NEWDIGS, Gigi Hirsch, MD, Sharon Phares, PhD, MPH, and Peter Neumann, ScD explore:
● Reasons why recent therapies’ impact were negatively affected by complicating real-world circumstances
● What progress some efforts are making and why they’re limited
● What important systemic barriers should be considered in value assessment
